Clark L N, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis E D, Cote L J, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K
Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, P&S Building, 14-434, 630 West 168th Street, New York, NY 10032, USA.
Neurology. 2006 Nov 28;67(10):1786-91. doi: 10.1212/01.wnl.0000244345.49809.36. Epub 2006 Oct 18.
To evaluate the frequency of leucine-rich repeat kinase gene (LRRK2) mutations and single nucleotide polymorphisms (SNPs) in early-onset Parkinson disease (EOPD) and late-onset Parkinson disease (LOPD).
We genotyped five previously reported LRRK2 mutations (G2019S, L1114L, I1122V, R1441C, and Y1699C) and 17 coding SNPs for haplotype analysis in 504 cases with PD and 314 controls enrolled in the Genetic Epidemiology of PD Study. Cases and controls were recruited without knowledge of family history of PD and cases were oversampled in the < or =50 age at onset (AAO) category.
The LRRK2 G2019S mutation was present in 28 cases with PD (5.6%) and two controls (0.6%) (chi(2) = 13.25; p < 0.01; odds ratio 9.18, 95% CI: 2.17 to 38.8). The mutations L1114L, I1122V, R1441C, and Y1699C were not identified. The frequency of the LRRK2 G2019S mutation was 4.9% in 245 cases with AAO < or =50 years vs 6.2% in 259 cases with AAO >50 (p = 0.56). All cases with PD with the G2019S mutation shared the same disease-associated haplotype. The frequency of the LRRK2 G2019S mutation was higher in the subset of 181 cases reporting four Jewish grandparents (9.9%) than in other cases (3.1%) (p < 0.01). Age-specific penetrance to age 80 was 24% and was similar in Jewish and non-Jewish cases.
The G2019S mutation is a risk factor in both early- and late-onset Parkinson disease and confirms the previous report of a greater frequency of the G2019S mutation in Jewish than in non-Jewish cases with Parkinson disease.
评估早发型帕金森病(EOPD)和晚发型帕金森病(LOPD)中富含亮氨酸重复激酶基因(LRRK2)突变及单核苷酸多态性(SNP)的频率。
我们对参与帕金森病遗传流行病学研究的504例帕金森病患者和314名对照进行基因分型,检测5个先前报道的LRRK2突变(G2019S、L1114L、I1122V、R1441C和Y1699C)以及17个编码SNP以进行单倍型分析。病例和对照的招募不知晓帕金森病家族史,且在发病年龄(AAO)≤50岁的类别中对病例进行了过度抽样。
28例帕金森病患者(5.6%)和2名对照(0.6%)存在LRRK2 G2019S突变(χ² = 13.25;p < 0.01;优势比9.18,95%置信区间:2.17至38.8)。未发现L1114L、I1122V、R1441C和Y1699C突变。在245例AAO≤50岁的患者中,LRRK2 G2019S突变频率为4.9%,而在259例AAO>50岁的患者中为6.2%(p = 0.56)。所有携带G2019S突变的帕金森病患者共享相同的疾病相关单倍型。在报告有四位犹太祖父母的181例患者亚组中,LRRK2 G2019S突变频率(9.9%)高于其他患者(3.1%)(p < 0.01)。至80岁的年龄特异性外显率为24%,在犹太和非犹太病例中相似。
G2019S突变是早发型和晚发型帕金森病的危险因素,并证实了先前关于帕金森病患者中G2019S突变在犹太人群中比非犹太人群中频率更高的报道。